Ram Gelman

A second-generation artificial intelligence-based therapeutic regimen improves diuretic resistance in heart failure: Results of a feasibility open-labeled clinical trial

2023 · 38 Zit. · Biomedicine & Pharmacotherapy

Improving the response to lenvatinib in partial responders using a Constrained-Disorder-Principle-based second-generation artificial intelligence-therapeutic regimen: a proof-of-concept open-labeled clinical trial

2024 · 16 Zit. · Frontiers in Oncology